Eric W. Linsley Managing General Partner
Eric W. Linsley is Managing General Partner of BioInnovation Capital. Eric oversees fund activities, runs our North Carolina lab, and focuses on opportunities
in therapeutics, laboratory tools, diagnostics, and devices. He has a long history of early stage life sciences investment success, most recently at
Pappas Ventures in Durham, NC. Prior to joining Pappas Ventures in 2000, Eric served as
Chief Financial Officer of TriPath Imaging, Inc.
(Nasdaq: TPTH), a medical device company in the Ampersand Ventures portfolio, which was
acquired in 2006 by Becton Dickinson. Eric played a key role in facilitating the three-way merger
between AutoCyte, NeoPath and Neuromedical Systems to form TriPath in 1999. Prior to the formation of TriPath, he was CFO of AutoCyte, one of the TriPath
predecessors, which completed an extremely successful public stock offering in 1997.
Eric was a partner at Ampersand Ventures, with Peter Parker, for several years in the mid-90’s. While at Ampersand, he held interim management positions
for various industrial products and life sciences companies. Early in his career, he served as a management consultant with Bain & Co. and McKinsey & Co. and was a Certified Public Accountant
with Arthur Andersen LLP.
At Pappas Ventures, Eric served on the Board of Panacos Pharmaceuticals (Nasdaq: PANC), also an Ampersand investment of Peter Parker’s, and played a key
role in its successful reverse merger with a publicly-traded company. He was directly responsible for investments in Peninsula Pharmaceuticals (acquired
by Johnson & Johnson acquired in 2005), and Cerexa (acquired by Forest Laboratories in 2007). Other representative investments included Balance Therapeutics, Envisia, FlowCardia (sold to BARD), LipoScience (Nasdaq: LPDX), Liquidia, Milestone Pharmaceuticals, Nuvasive (Nasdaq: NUVA) and Ultragenyx (Nasdaq: RARE). During his tenure at Pappas Ventures, Eric’s team also invested in Achillion (Nasdaq: ACHN), Chimerix, (Nasdaq: CMRX), Lumena (sold to Shire), Plexxikon (sold to Daiichi Sankyo),
Tesaro (Nasdaq: TSRO), and TyRx (sold to Medtronic).